TBC Abbvie Pty Ltd
Product name
TBC
Sponsor
Accepted date
Nov-2023
Active ingredients
Risankizumab
Proposed indication
For the treatment of moderately to severely active ulcerative colitis.
Application type
C (new indication)
Publication date
Nov-2023